董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas H. Jensen | 男 | Chief Executive Officer and Director | 47 | 145.90万美元 | 未持股 | 2026-03-20 |
| Jesper Hoiland | -- | Director | -- | 3.33万美元 | 未持股 | 2026-03-20 |
| Laura E. Benjamin | -- | Director | -- | 9.18万美元 | 未持股 | 2026-03-20 |
| Gerald W. McLaughlin | 男 | Chairman of Board and Director | 58 | 13.08万美元 | 未持股 | 2026-03-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey S. Ervin | 男 | Chief Financial Officer | 48 | 15.85万美元 | 未持股 | 2026-03-20 |
| Steen Knudsen | 男 | Chief Scientific Officer | 65 | 23.68万美元 | 未持股 | 2026-03-20 |
| Jeremy R. Graff | 男 | Chief Development Officer and President | 56 | 90.88万美元 | 2.49 | 2026-03-20 |
董事简历
中英对照 | 中文 | 英文- Thomas H. Jensen
-
Thomas H.Jensen自2020年6月以来一直担任我们的前身Allarity Therapeutics A/S的信息技术高级副总裁，并继续担任我们的信息技术高级副总裁。Jensen先生曾于2004年至2020年6月担任我们前任的首席技术官。Jensen先生于2004年共同创立Allarity Therapeutics A/S。Jensen先生还在丹麦建立并领导我们的实验室。除了培育我们的全球实验室，Jensen先生在建立我们的投资者关系运营，获得运营融资以及促进Allarity Therapeutics的业务增长方面发挥了重要作用。Jensen先生的荣誉之一是他的分子生物学指南的发明，结合了高质量可重复的RNA提取和下游加工技术。这允许对癌症患者的活检进行高分辨率分析。Jensen先生的发明是DRP®；药物反应预测平台的重要基础。Jensen先生拥有丹麦技术大学的生物学学士学位，并在哥本哈根大学进行了生物学的进一步研究。
Thomas H. Jensen has been the Chief Executive Officer of Allarity Therapeutics, Inc. since December 2023, a director of ours since July 2022, and has been a part of the Company's since its inception serving in a range of capacities. Before becoming the CEO, Mr. Jensen has been the Senior Vice President, Investor Relations since June 2022, and a director of ours since July 2022. Previously, Mr. Jensen served as Senior Vice President of information Technology of Allarity Therapeutics, Inc. as well as of Allarity Therapeutics, Inc.'s predecessor, Allarity Therapeutics A/S, since June 2020. Mr. Jensen previously served as the Chief Technology Officer of Allarity Therapeutics, Inc.'s predecessor from 2004 to June 2020. Mr. Jensen co founded Allarity Therapeutics A/S in 2004. Mr. Jensen also established and currently leads Allarity Therapeutics, Inc.'s laboratories in Denmark. Alongside nurturing Allarity Therapeutics, Inc.'s global laboratories, Mr. Jensen is instrumental in building Allarity Therapeutics, Inc.'s investor relations operations, securing operational financing, and fostering the business growth of Allarity Therapeutics. Amongst Mr. Jensen's accolades are his inventions of molecular biological guidelines combined with techniques for high quality reproducible RNA extraction and downstream processing. This allows for high resolution analysis of cancer patients' biopsies. Mr. Jensen's inventions are an important foundation of the DRP Drug Response Prediction platform. Mr. Jensen also currently serves on the Board of Cardeon AB, a Swedish company that invests in innovative Nordic companies and start ups in medical technology and Life Science. Mr. Jensen holds a Bachelor of Science degree in Biology from the Technical University of Denmark, and conducted further studies in Biology at the University of Copenhagen. - Thomas H.Jensen自2020年6月以来一直担任我们的前身Allarity Therapeutics A/S的信息技术高级副总裁，并继续担任我们的信息技术高级副总裁。Jensen先生曾于2004年至2020年6月担任我们前任的首席技术官。Jensen先生于2004年共同创立Allarity Therapeutics A/S。Jensen先生还在丹麦建立并领导我们的实验室。除了培育我们的全球实验室，Jensen先生在建立我们的投资者关系运营，获得运营融资以及促进Allarity Therapeutics的业务增长方面发挥了重要作用。Jensen先生的荣誉之一是他的分子生物学指南的发明，结合了高质量可重复的RNA提取和下游加工技术。这允许对癌症患者的活检进行高分辨率分析。Jensen先生的发明是DRP®；药物反应预测平台的重要基础。Jensen先生拥有丹麦技术大学的生物学学士学位，并在哥本哈根大学进行了生物学的进一步研究。
- Thomas H. Jensen has been the Chief Executive Officer of Allarity Therapeutics, Inc. since December 2023, a director of ours since July 2022, and has been a part of the Company's since its inception serving in a range of capacities. Before becoming the CEO, Mr. Jensen has been the Senior Vice President, Investor Relations since June 2022, and a director of ours since July 2022. Previously, Mr. Jensen served as Senior Vice President of information Technology of Allarity Therapeutics, Inc. as well as of Allarity Therapeutics, Inc.'s predecessor, Allarity Therapeutics A/S, since June 2020. Mr. Jensen previously served as the Chief Technology Officer of Allarity Therapeutics, Inc.'s predecessor from 2004 to June 2020. Mr. Jensen co founded Allarity Therapeutics A/S in 2004. Mr. Jensen also established and currently leads Allarity Therapeutics, Inc.'s laboratories in Denmark. Alongside nurturing Allarity Therapeutics, Inc.'s global laboratories, Mr. Jensen is instrumental in building Allarity Therapeutics, Inc.'s investor relations operations, securing operational financing, and fostering the business growth of Allarity Therapeutics. Amongst Mr. Jensen's accolades are his inventions of molecular biological guidelines combined with techniques for high quality reproducible RNA extraction and downstream processing. This allows for high resolution analysis of cancer patients' biopsies. Mr. Jensen's inventions are an important foundation of the DRP Drug Response Prediction platform. Mr. Jensen also currently serves on the Board of Cardeon AB, a Swedish company that invests in innovative Nordic companies and start ups in medical technology and Life Science. Mr. Jensen holds a Bachelor of Science degree in Biology from the Technical University of Denmark, and conducted further studies in Biology at the University of Copenhagen.
- Jesper Hoiland
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Laura E. Benjamin
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Gerald W. McLaughlin
-
Gerald W. McLaughlin于2012年10月起担任Nupathe Inc.副总裁兼首席商务官，在此之前，于2007年9月起担任副总裁。在加入NuPathe之前，McLaughlin先生曾在Endo Pharmaceuticals一家专业制药公司担任过多种职务，包括从2007年1月至2007年8月担任战略营销高级总监，从2005年7月至2006年12月担任区域销售总监，从2002年11月至2005年6月担任止痛产品集团营销总监，以及营销总监。在此之前，McLaughlin先生曾在默克公司担任过11年的各种营销和销售职务。McLaughlin先生拥有Dickinson College的学士学位和维拉诺瓦大学的MBA学位。
Gerald W. McLaughlin has served as Nupathe Inc. Vice President and Chief Commercial Officer since October 2012 and prior to that, as Vice President, Commercial Operations since September 2007. Prior to joining NuPathe, Mr. McLaughlin served in a variety of roles at Endo Pharmaceuticals, a specialty pharmaceutical company, including Senior Director, Strategic Marketing from January 2007 through August 2007 Regional Sales Director from July 2005 through December 2006 Group Marketing Director, Pain Products from November 2002 through June 2005 and Marketing Director. Prior to that, Mr. McLaughlin served in a variety of marketing and sales roles at Merck for 11 years. Mr. McLaughlin holds a BA from Dickinson College and an MBA from Villanova University. - Gerald W. McLaughlin于2012年10月起担任Nupathe Inc.副总裁兼首席商务官，在此之前，于2007年9月起担任副总裁。在加入NuPathe之前，McLaughlin先生曾在Endo Pharmaceuticals一家专业制药公司担任过多种职务，包括从2007年1月至2007年8月担任战略营销高级总监，从2005年7月至2006年12月担任区域销售总监，从2002年11月至2005年6月担任止痛产品集团营销总监，以及营销总监。在此之前，McLaughlin先生曾在默克公司担任过11年的各种营销和销售职务。McLaughlin先生拥有Dickinson College的学士学位和维拉诺瓦大学的MBA学位。
- Gerald W. McLaughlin has served as Nupathe Inc. Vice President and Chief Commercial Officer since October 2012 and prior to that, as Vice President, Commercial Operations since September 2007. Prior to joining NuPathe, Mr. McLaughlin served in a variety of roles at Endo Pharmaceuticals, a specialty pharmaceutical company, including Senior Director, Strategic Marketing from January 2007 through August 2007 Regional Sales Director from July 2005 through December 2006 Group Marketing Director, Pain Products from November 2002 through June 2005 and Marketing Director. Prior to that, Mr. McLaughlin served in a variety of marketing and sales roles at Merck for 11 years. Mr. McLaughlin holds a BA from Dickinson College and an MBA from Villanova University.
高管简历
中英对照 | 中文 | 英文- Jeffrey S. Ervin
Jeffrey S. Ervin， Ddc Enterprise Limited联席首席财务官。他于2015年3月共同创立了IMAC Holdings， Inc.（纳斯达克股票代码：BACK），并担任其首席执行官兼董事会主席，直到2024年5月。2011年10月至2015年3月，Ervin先生担任Medicare.com母公司Medx Publishing的高级财务官，负责建立行政职能，以满足CMS教育部门的快速增长。在此期间至2015年3月，Medicare.com获得INC. 500的认可，他在收购Medicaid.com（出售给United Healthcare Group）的过程中发挥了重要作用。2006年至2011年9月，Ervin先生担任纳什维尔浸信会医院系统的高级财务分析师和财务副总裁，负责采购和管理直接投资以满足养老金义务。他在范德比尔特大学获得工商管理硕士学位，在迈阿密大学获得金融学士学位。
Jeffrey S. Ervin has served on Board since February 2024. Mr. Ervin has served as Chief Financial Officer of Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical stage, precision medicine company actively advancing a pipeline of in licensed oncology therapeutics, since July 2025. From June 2024 to January 2025, he served in a fractional capacity as co chief financial officer of DDC Enterprise, Ltd (NYSE: DDC). Prior to DDC, he served as chairman and chief executive officer of IMAC Holdings, Inc. between February 2015 and May 2024. Mr. Ervin was co founder of IMAC Holdings, Inc. and led an initial public offering in February 2019 (Nasdaq: BACK). Mr. Ervin earned his Master of Business Administration from Vanderbilt University and his Bachelor of Science in Finance from Miami University.- Jeffrey S. Ervin， Ddc Enterprise Limited联席首席财务官。他于2015年3月共同创立了IMAC Holdings， Inc.（纳斯达克股票代码：BACK），并担任其首席执行官兼董事会主席，直到2024年5月。2011年10月至2015年3月，Ervin先生担任Medicare.com母公司Medx Publishing的高级财务官，负责建立行政职能，以满足CMS教育部门的快速增长。在此期间至2015年3月，Medicare.com获得INC. 500的认可，他在收购Medicaid.com（出售给United Healthcare Group）的过程中发挥了重要作用。2006年至2011年9月，Ervin先生担任纳什维尔浸信会医院系统的高级财务分析师和财务副总裁，负责采购和管理直接投资以满足养老金义务。他在范德比尔特大学获得工商管理硕士学位，在迈阿密大学获得金融学士学位。
- Jeffrey S. Ervin has served on Board since February 2024. Mr. Ervin has served as Chief Financial Officer of Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical stage, precision medicine company actively advancing a pipeline of in licensed oncology therapeutics, since July 2025. From June 2024 to January 2025, he served in a fractional capacity as co chief financial officer of DDC Enterprise, Ltd (NYSE: DDC). Prior to DDC, he served as chairman and chief executive officer of IMAC Holdings, Inc. between February 2015 and May 2024. Mr. Ervin was co founder of IMAC Holdings, Inc. and led an initial public offering in February 2019 (Nasdaq: BACK). Mr. Ervin earned his Master of Business Administration from Vanderbilt University and his Bachelor of Science in Finance from Miami University.
- Steen Knudsen
Steen Knudsen自2006年以来一直担任我们前任的首席科学官，并继续担任我们的首席科学官。Knudsen博士是Allarity Therapeutics A/S的联合创始人，也是药物反应预测平台DRP®；的发明者，DRP®；是我们的核心技术和伴随诊断平台。Knudsen博士还是系统生物学的前教授，在数学，生物信息学，生物技术和系统生物学方面拥有丰富的专业知识。他于2004年联合创立了我们的前身公司，并于2004年至2006年担任其首席执行官。Knudsen博士此前还曾于2016年至2020年担任我们前任董事会的成员。此外，Knudsen博士目前还担任MPI，Inc.（我们在美国的运营子公司）的首席执行官。丹麦技术大学工程学学位和哥本哈根大学微生物学博士学位。他在哈佛医学院接受了计算生物学博士后培训。
Steen Knudsen has been Chief Scientific Officer since July 2021. Dr. Knudsen is a co founder of Allarity Therapeutics, Inc.'s predecessor Allarity Therapeutics A/S and the inventor of DRP, the Drug Response Prediction Platform, which is Allarity Therapeutics, Inc.'s core technology and companion diagnostics platform, and was the Chief Scientific Officer of Allarity Therapeutics A/S since 2006. Dr. Knudsen is also a former Professor of Systems Biology with extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology. He co founded Allarity Therapeutics, Inc.'s predecessor in 2004 and served as its Chief Executive Officer from 2004 to 2006. Dr. Knudsen also previously served as a member on Allarity Therapeutics, Inc.'s predecessor's board of directors from 2016 to 2020. In addition, Dr. Knudsen also currently serves as the Chief Executive Officer of MPI, Inc., Allarity Therapeutics, Inc.'s operating subsidiary in the U.S. Dr. Knudsen holds an M.Sc. degree in Engineering from the Technical University of Denmark and a Ph.D. degree in Microbiology from the University of Copenhagen. He received Postdoctoral training in computational biology from Harvard Medical School.- Steen Knudsen自2006年以来一直担任我们前任的首席科学官，并继续担任我们的首席科学官。Knudsen博士是Allarity Therapeutics A/S的联合创始人，也是药物反应预测平台DRP®；的发明者，DRP®；是我们的核心技术和伴随诊断平台。Knudsen博士还是系统生物学的前教授，在数学，生物信息学，生物技术和系统生物学方面拥有丰富的专业知识。他于2004年联合创立了我们的前身公司，并于2004年至2006年担任其首席执行官。Knudsen博士此前还曾于2016年至2020年担任我们前任董事会的成员。此外，Knudsen博士目前还担任MPI，Inc.（我们在美国的运营子公司）的首席执行官。丹麦技术大学工程学学位和哥本哈根大学微生物学博士学位。他在哈佛医学院接受了计算生物学博士后培训。
- Steen Knudsen has been Chief Scientific Officer since July 2021. Dr. Knudsen is a co founder of Allarity Therapeutics, Inc.'s predecessor Allarity Therapeutics A/S and the inventor of DRP, the Drug Response Prediction Platform, which is Allarity Therapeutics, Inc.'s core technology and companion diagnostics platform, and was the Chief Scientific Officer of Allarity Therapeutics A/S since 2006. Dr. Knudsen is also a former Professor of Systems Biology with extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology. He co founded Allarity Therapeutics, Inc.'s predecessor in 2004 and served as its Chief Executive Officer from 2004 to 2006. Dr. Knudsen also previously served as a member on Allarity Therapeutics, Inc.'s predecessor's board of directors from 2016 to 2020. In addition, Dr. Knudsen also currently serves as the Chief Executive Officer of MPI, Inc., Allarity Therapeutics, Inc.'s operating subsidiary in the U.S. Dr. Knudsen holds an M.Sc. degree in Engineering from the Technical University of Denmark and a Ph.D. degree in Microbiology from the University of Copenhagen. He received Postdoctoral training in computational biology from Harvard Medical School.
- Jeremy R. Graff
Jeremy R. Graff在生物技术/制药行业工作了超过25年，在靶向小分子和大分子疗法以及新型免疫疗法的临床前和临床开发方面积累了深厚的经验和专业知识。此前，格拉夫博士曾在多家生物技术公司担任C级和高级管理职位。2023年11月至2024年9月，Graff博士担任公司顾问，就公司在小分子抑制剂领域的研发项目及其在癌症治疗中的应用提供咨询和咨询服务。自2024年1月以来，Graff博士还担任多家公司的C Suite执行顾问和顾问。2021年6月至2024年1月，Graff博士在加拿大早期生物技术公司IMV公司担任首席科学官。格拉夫在约翰霍普金斯大学医学院完成了博士后研究金。他拥有肯塔基大学马基癌症中心的博士学位，以及托马斯莫尔学院（现为托马斯莫尔大学）的生物学和化学文学学士学位。
Jeremy R. Graff has worked in the Biotech/Pharma industry for more than 25 years, garnering deep experience and expertise in the preclinical and clinical development of targeted small and large molecule therapeutics as well as novel immunotherapeutics. Previously, Dr. Graff held C level and senior executive positions at various biotechnology companies. Form November 2023 to September 2024, Dr. Graff served as a consultant to the Company providing consulting and advisory services on the Company's research and development programs in the field of small molecule inhibitors and their use in the treatment of cancer. Since January of 2024, Dr. Graff has also served as a C Suite Executive Advisor and Consultant to a number of companies. From June 2021 to January 2024, Dr. Graff served as the Chief Scientific Officer at IMV, Inc., an early stage Canadian biotechnology company.Dr. Graff completed a post doctoral fellowship at the Johns Hopkins University School of Medicine. He holds a Ph.D. from the University of Kentucky's Markey Cancer Center, and a Bachelor of Arts degree in Biology and Chemistry from Thomas More College (now Thomas More University).- Jeremy R. Graff在生物技术/制药行业工作了超过25年，在靶向小分子和大分子疗法以及新型免疫疗法的临床前和临床开发方面积累了深厚的经验和专业知识。此前，格拉夫博士曾在多家生物技术公司担任C级和高级管理职位。2023年11月至2024年9月，Graff博士担任公司顾问，就公司在小分子抑制剂领域的研发项目及其在癌症治疗中的应用提供咨询和咨询服务。自2024年1月以来，Graff博士还担任多家公司的C Suite执行顾问和顾问。2021年6月至2024年1月，Graff博士在加拿大早期生物技术公司IMV公司担任首席科学官。格拉夫在约翰霍普金斯大学医学院完成了博士后研究金。他拥有肯塔基大学马基癌症中心的博士学位，以及托马斯莫尔学院（现为托马斯莫尔大学）的生物学和化学文学学士学位。
- Jeremy R. Graff has worked in the Biotech/Pharma industry for more than 25 years, garnering deep experience and expertise in the preclinical and clinical development of targeted small and large molecule therapeutics as well as novel immunotherapeutics. Previously, Dr. Graff held C level and senior executive positions at various biotechnology companies. Form November 2023 to September 2024, Dr. Graff served as a consultant to the Company providing consulting and advisory services on the Company's research and development programs in the field of small molecule inhibitors and their use in the treatment of cancer. Since January of 2024, Dr. Graff has also served as a C Suite Executive Advisor and Consultant to a number of companies. From June 2021 to January 2024, Dr. Graff served as the Chief Scientific Officer at IMV, Inc., an early stage Canadian biotechnology company.Dr. Graff completed a post doctoral fellowship at the Johns Hopkins University School of Medicine. He holds a Ph.D. from the University of Kentucky's Markey Cancer Center, and a Bachelor of Arts degree in Biology and Chemistry from Thomas More College (now Thomas More University).